Legend Biotech is a global, clinical-stage biotechnology company developing and manufacturing novel therapies. We explore and apply innovative technologies to deliver safe, efficacious and cutting-edge options for patients around the world.
We came together as a team of experts, committed to quality, driven by excellence, and dedicated to experimentation. Though we faced many challenges, we remained fearless in our research and rigorous in our thinking, as we push ourselves to work harder.
What keeps us moving is the enormous burden patients bear and the difficulties they face.
We believe it’s time to accelerate and expand that transformation. At Legend Biotech, we are excited to bring clinical trials to patients in our pursuit of a cure. While we are focused on CAR-T in multiple myeloma, we firmly believe the prospects of cellular therapy stretch beyond just one disease or indication.
The spark of hope is lit. At Legend Biotech, we're using that hope to ignite the future of CAR-T cell therapy.
We came together as a team of experts, committed to quality, driven by excellence, and dedicated to experimentation. Though we faced many challenges, we remained fearless in our research and rigorous in our thinking, as we push ourselves to work harder.
What keeps us moving is the enormous burden patients bear and the difficulties they face.
We believe it’s time to accelerate and expand that transformation. At Legend Biotech, we are excited to bring clinical trials to patients in our pursuit of a cure. While we are focused on CAR-T in multiple myeloma, we firmly believe the prospects of cellular therapy stretch beyond just one disease or indication.
The spark of hope is lit. At Legend Biotech, we're using that hope to ignite the future of CAR-T cell therapy.
Location: United States, New Jersey
Employees: 501-1000
Total raised: $150.5M
Founded date: 2014
Investors 3
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | RA Capital... | racap.com |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.04.2020 | Series A | $150.5M | - |
Mentions in press and media 25
| Date | Title | Description |
| 31.08.2026 | Singapore’s biotechnology firm K2 Therapeutics raises $50 M Seed funding from MPM BioImpact | The U.S. investment firm MPM BioImpact, which formed Singapore-based biotechnology business K2 Therapeutics in 2024, has provided $50 million in seed funding. K2 Therapeutics said in a statement on Tuesday that the funding has enabled the c... |
| 08.12.2025 | China Releases First Novel Drugs List for Commercial Insurance, With CAR-T Therapies Leading the Way | (Yicai) Dec. 8 -- China introduced its first Commercial Health Insurance Innovative Drug List that includes five chimeric antigen receptor-T cell therapies, which re-engineer a patient's own white blood cells to recognize and attack cancer,... |
| 30.10.2025 | Innovent’s tie-up with Takeda tests investor faith in China’s biotech dream | Since early October, shares of China’s innovative drugmakers have trended downward. As investors quipped about the need for another major deal to restore confidence, one such event finally arrived. On October 22, Innovent Biologics announce... |
| 20.10.2025 | Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London | PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future o... |
| 01.08.2025 | Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland | HONG KONG SAR – Media OutReach Newswire – 1 August 2025 – Cushman & Wakefield, a leading global real estate services firm, today released its Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences re... |
| 25.10.2024 | Innovations in Drug Delivery: A Leap Towards the Future | In the ever-evolving landscape of healthcare, innovation is the lifeblood that keeps the industry vibrant. Recently, two significant events showcased groundbreaking advancements in drug delivery and biopharmaceuticals. The PDA Universe of P... |
| 24.10.2024 | Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights | PISCATAWAY, N.J., Oct. 24, 2024 /PRNewswire/ -- Cell therapy, gene therapy, and mRNA vaccines are revolutionizing healthcare, offering innovative treatments for a wide range of diseases. However, as these therapies progress, they encounter ... |
| 30.09.2024 | The Rising Tide of Chinese Biopharmaceuticals: A Global Perspective | The biopharmaceutical landscape is shifting. Chinese companies are no longer just local players; they are emerging as global contenders. The recent collaboration between Anbogen and BeiGene exemplifies this trend. Anbogen, a clinical-stage ... |
| 28.09.2024 | Frost & Sullivan Released Report: "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" | SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Frost & Sullivan released the "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" which focus on the progress of Chinese biopharmaceuticals going glob... |
| 15.09.2024 | Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together | PISCATAWAY, N.J., Sept. 15, 2024 /PRNewswire/ -- The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a ... |
Show more